The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C01 | Cardiac therapy | |
| 3 | C01E | Other cardiac preparations | |
| 4 | C01EB | Other cardiac preparations | |
| 5 | C01EB21 |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 0.4 mg |
| Active Ingredient | Description | |
|---|---|---|
| Regadenoson |
Regadenoson is a low affinity agonist (Ki â 1.3 ΞM) for the A2A adenosine receptor, with at least 10-fold lower affinity for the A1 adenosine receptor (Ki >16.5 ΞM), and very low, if any, affinity for the A2B and A3 adenosine receptors. Activation of the A2A adenosine receptor produces coronary vasodilation and increases coronary blood flow (CBF). |
| Title | Information Source | Document Type | |
|---|---|---|---|
| RAPISCAN Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
